Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Entinostat + Nivolumab + Ipilimumab in RCC
NCT03552380Phase 2Terminated
- Start
- Jul 2018
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of entinostat in renal cell carcinoma (RCC). Started Jul 2018; status: terminated.
02
Drugs
entinostat
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT03552380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03552380.